Lifestyle
More cancer patients die here than in US, South Korea, Japan: Paper
More than double the number of cancer patients in Singapore die of the disease compared with those in Australia and the United States. In Asia, Singapore also fares worse than South Korea and Japan in terms of cancer survival rate. Doctors say facto
More than double the number of cancer patients in Singapore die of the disease compared with those in Australia and the United States. In Asia, Singapore also fares worse than South Korea and Japan in terms of cancer survival rate.
Doctors say factors such as age at diagnosis, screening take-up rates and access to care are among possible reasons for the lower survival rate here.
A paper published by the Asia-Pacific Medical Technology Association (ApacMed) in June showed that 51 out of 100 cancer patients in Singapore die, compared with 24 in Australia, 25 in the US, 38 in South Korea and 41 in Japan.
The paper suggests that countries with higher cancer mortality rates are the ones with lower use of next-generation sequencing (NGS), a test that identifies biomarkers in cancers that can be targeted with specific treatments, resulting in better outcomes.
ApacMed, which represents manufacturers and suppliers of medical equipment, devices and in-vitro diagnostics, clearly has an interest in pushing for NGS.
Doctors say factors such as age at diagnosis, screening take-up rates and access to care are among possible reasons for the lower survival rate here.
A paper published by the Asia-Pacific Medical Technology Association (ApacMed) in June showed that 51 out of 100 cancer patients in Singapore die, compared with 24 in Australia, 25 in the US, 38 in South Korea and 41 in Japan.
The paper suggests that countries with higher cancer mortality rates are the ones with lower use of next-generation sequencing (NGS), a test that identifies biomarkers in cancers that can be targeted with specific treatments, resulting in better outcomes.
ApacMed, which represents manufacturers and suppliers of medical equipment, devices and in-vitro diagnostics, clearly has an interest in pushing for NGS.